Efficacy and safety in clinical practice fosinopril

Cover Page

Cite item

Full Text

Abstract

Diseases of the cardiovascular system, including the leading place is occupied arterial hypertension (AH), making the most significant contribution to the statistics of fatal and disabling complications in the industrialized world, including in Russia. For the treatment of hypertension, according to domestic and European recommendations, 5 main groups of drugs, are applied including a significant role for blockers of the renin-angiotensin-aldosterone system. Among the angiotensin converting enzyme inhibitors deserved place on clinical effectiveness, organo properties and safety profile belongs fosinopril - lipophilic drug with a dual route of elimination. These properties fosinopril have sufficient evidentiary basis, and despite the large variety of drugs in this group, fosinopril has its own niche in the treatment of hypertensive patients, including those with concomitant chronic kidney disease, chronic heart failure, and has future prospects.

About the authors

R. I Stryuk

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: rstryuk@list.ru
д-р мед. наук, проф., засл. врач РФ, зав. каф. внутренних болезней стоматологического факультета ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

References

  1. Heidenreich P.A, Trogdon J.G, Khavjou O.A et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123 (8): 933-44.
  2. Чазова И.Е., Ратова Л.Г., Бойцов С.А. и др. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 3-26.
  3. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.
  4. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.
  5. Ceconi С, Francolini G, Bastianon D et al. Differences in the effect of angiotensin - converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007; 21 (6): 423-9.
  6. Стрюк Р.И., Петрова Т.В., Орлова Т.А., Нагорнев С.Н. Клиническая эффективность фозиноприла у больных гипертонической болезнью в сочетании с метаболическими нарушениями. Кардиология. 1999; 7: 13-6. / Striuk R.I., Petrova T.V., Orlova T.A., Nagornev S.N. Klinicheskaia effektivnost' fozinoprila u bol'nykh gipertonicheskoi bolezn'iu v sochetanii s metabolicheskimi narusheniiami. Kardiologiia. 1999; 7: 13-6. [in Russian]
  7. Rosolova H, Cech J, Sefma F. Effectiveness and tolerance of fosinopril in the treatment of arterial hypertension of mild and medium seventy. Vnitr Lek 2001; 47: 834-9.
  8. Yu C.M, Wing-Hon Lai K, Li P.S et al. Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action. J Mol Cell Cardiol 2004; 36: 445-53.
  9. Карпов Ю.А. Фозиноприл при лечении артериальной гипертонии (ФЛАГ): Российская программа оценки практической достижимости целевых уровней артериального давления. Рус. мед. журн. 2001; 10: 396-401.
  10. Чазова И.Е. Первые результаты исследования ФАГОТ (Фармакоэкономическая оценка использования ингибиторов АПФ в амбулаторном лечении больных с артериальной гипертонией осложненного течения). Consillium Medicum. 2002; 11: 596-8.
  11. Мареев В.Ю. Фармакоэкономическая оценка использования иАПФ в амбулаторном лечении больных с сердечной недостаточностью (ФАСОН). Сердечная недостаточность. 2002; 3 (1): 38-9.
  12. Asselbergs F.W, Diercks G.F, Hillege H.L et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110 (18): 2809-16.
  13. Electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study. Circulation (LIFE) 2009; 119: 1883-91.
  14. Böhm M, Thoenes M, Danchin N et al. Overview of the i-SEARCH Global Study: Cardiovascular Risk Factors and Microalbuminuria in Hypertensive Individuals. See comment in PubMed Commons below. High Blood Press Cardiovasc Prev 2008; 15 (4): 217-24.
  15. Хохлов А.Л., Шуникова М.И., Соснин А.Ю. и др. Гемодинамические показатели у больных артериальной гипертонией на фоне терапии амлодипином, фозиноприлом и метопрололом. Рацион. фармакотерапия в кардиологии. 2007; 4 (3): 33-8.
  16. Брыткова Я.В., Гомова И.С., Татаринова О.В., Стрюк Р.И. Нефропротективный эффект антигипертензивной терапии у женщин с артериальной гипертонией в перименопаузе. Проблемы женского здоровья. 2014; 2 (9): 23-5.
  17. Choudary J, Kini S.G, Ranganath Pai et al. Docking studies and biological activity of fosinopril analogs. Int J Med Chem 2014; 2014: 721-834.
  18. Medhora M, Gao F, Wu Q et al. Model development and use of ACE inhibitors for preclinical mitigation of radiation - induced injury to multiple organs. Radiat Res 2014; 182 (5): 545-55.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies